iNOS


Also found in: Medical.
AcronymDefinition
iNOSInducible Nitric Oxide Synthase (aka Inducible Isoform of Nitric Oxide Synthase)
INOSImproved Neds Operating System
References in periodicals archive ?
Induction of iNOS expression and hence NO production has been described to have beneficial and detrimental consequences and seems to be involved in the pathophysiology of different human diseases.
Normal and NSIP histological patterns of alveolar septa and vessels are shown in Figures 1, 2, and 3, with immunohistochemical staining by nNOS (Figure 1, left panels), eNOS (Figure 1, middle panels), and iNOS (Figure 1, right panels); PAI-1 (Figure 2, left panels), [alpha]-SMA (Figure 2, middle panels), and IL-4 (Figure 2, right panels); IL-13 (Figure 3, left panels), and bFGF (Figure 3, right panels).
The Inos caravan, launched in 2011, was Europe's first production line caravan with a slide-out compartment creating an extra 4.
The Parry-Jones family celebrate their exclusive German partnership with Roka in front of their Inos caravan
These transcription factors allow the blueprint of DNA to bind with proteins that continue the signal cascade, eventually leading to the production of harmful COX2 and iNOS.
Because SCD is associated with oxidative stress, increased expression of endothelial cell adhesion molecules, and blood cell adhesion, which are characteristic features of an inflammatory response, several researchers have studied the role of iNOS in SCD (7).
It was also found that curcumin was a more potent inhibitor of iNOS gene expression than bisdemethoxycurcumin.
The addition of iNOS and PPAR gamma brings the total number of available targets in ActiveSight's Protein Portfolio to fourteen.
11-18) In patients with allergic rhinitis, increased iNOS expression caused by the release of proinflammatory cytokines in the upper and lower respiratory tract mucosae has emerged as a possible cause of increased NO levels.
The current clinical trials of our sepsis product are designed to show just how important human iNOS might be in the early diagnosis and management of patients at highest risk for developing sepsis.
Japanese Patent Application #2003-517204 covers very broadly the use of R&D Antibodies' immunoassays, assay kits, and apparatuses for the detection of plasma iNOS as an early biomarker for the prognosis and diagnosis of the life-threatening sepsis pathology.